Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-11-09

FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Original Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved Teva's generic fixed-dose combination efavirenz/emtricitabine/tenofovir disoproxil fumarate for HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (Efavirenz; Emtricitabine; Tenofovir disoproxil fumarate)

Snippet

ORIG AP for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)